P&G Builds Heartburn Market Lead, Continues Focus On Whitening Products
This article was originally published in The Tan Sheet
Executive Summary
Prilosec OTC's sustained momentum helped produce a 17% gain in unit volume for Procter & Gamble's health care segment in the second quarter (ended Dec. 31). Sales for the unit rose 22% to $1.91 bil. and earnings advanced 32% to $333 mil
You may also be interested in...
AstraZeneca Says Prilosec OTC Sales “Flattish” In The First Quarter
Sales of Procter & Gamble's Prilosec OTC leveled off in the first quarter compared to the three months of its initial launch last year, according to AstraZeneca
AstraZeneca Says Prilosec OTC Sales “Flattish” In The First Quarter
Sales of Procter & Gamble's Prilosec OTC leveled off in the first quarter compared to the three months of its initial launch last year, according to AstraZeneca
AstraZeneca Says Prilosec OTC Sales “Flattish” In The First Quarter
Sales of Procter & Gamble's Prilosec OTC leveled off in the first quarter compared to the three months of its initial launch last year, according to AstraZeneca